America’s drug lobby invested heavily in search advertising as the political fight over medicine costs intensified, with a new analysis estimating that the Pharmaceutical Research & Manufacturers of America spent about $59 million over seven years to influence how people encountered information on prescription drugs online. The spending covered the period from 2019 through 2025 and was designed to capture users searching for terms linked to insurance, health plans and the forces behind high out-of-pocket costs.
The analysis, published in Clinical Pharmacology & Therapeutics, modeled paid search activity and found that PhRMA used more than 283,500 distinct keywords to generate 17.1 million paid visits. Roughly $32 million was tied to searches involving insurance and health plans. Another estimated $28 million directed users toward pages and domains criticizing pharmacy benefit managers, the intermediaries that negotiate drug benefits for insurers, employers and government programs.
The campaign highlights a central fault line in the U.S. health care debate. Drugmakers have argued that pharmacy benefit managers play a major role in keeping medicine costs high by shaping formularies, negotiating rebates and affecting patient access. Critics of the pharmaceutical industry, however, have focused on the launch prices set by manufacturers and the cumulative cost of branded medicines. Search advertising allowed the industry’s trade group to place its preferred explanations in front of users at the moment they were looking for information on a politically sensitive subject.
Spending rose around major policy moments, including the start of Medicare drug price negotiations in 2023, a key provision implemented through the federal government’s effort to lower costs for older Americans. The program, administered by the Centers for Medicare & Medicaid Services, marked a significant shift in Washington’s approach to pharmaceutical pricing, giving the government a direct role in negotiating prices for selected medicines covered by Medicare.
The findings point to the growing importance of paid search in policy disputes, where public opinion can be shaped outside traditional advertising channels. For the pharmaceutical industry, search ads offered a targeted way to frame responsibility for drug costs during years of heightened scrutiny in the United States. The scale of the campaign also underscores how digital advertising has become part of lobbying strategy, especially when legislation and regulation threaten to alter a sector’s business model.
